Exelixis (NasdaqGS:EXEL) recently announced positive topline results from the STELLAR-303 Phase 3 trial, highlighting the ...

EXEL jumps 7.4% as STELLAR-303 trial hits key survival goal in colorectal cancer, boosting hopes for an approval of ...

Revenue: Total revenue was $1.3 million for Q1 2025, up from $1.2 million in Q4 2024. Both figures reflect approximately a 50% decline year-over-year due to the sale of the Lori Goldstein brand in ...